← 產業報告目錄
Neoantigen Peptides Manufacturing Market Size, Share & Trends Analysis Report By Scale of Operations (Research/Preclinical, Clinical, Commercial), By End-Users (Pharmaceutical/Vaccine developers companies, Contract Research Organizations, Academic and research institutes, Region And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-10頁數 170報告編號 INSIGHTACE-3f9dea500f
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The Neoantigen Peptides Manufacturing Market on a global scale was estimated at USD 1.4 Billion in 2024 and is expected to attain USD 6.3 Billion by 2034, with a projected CAGR of 16.4% between 2025 and 2034.
At its core, Neoantigen Peptides Manufacturing pertains to key industry insights & findings from the report:
The escalating prevalence of cancer as well as other chronic illnesses represents a major factor driving the growth of the neoantigen peptides manufacturing . Stakeholders across the healthcare landscape are escalatingly turning to these solutions to meet contemporary demands.
Growth is driven by a convergence of factors: rising awareness among end users, continuous product innovation, and the escalating emphasis on efficiency and sustainability within the healthcare sector.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region expected to deliver the strongest growth trajectory through the forecast period, driven by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neoantigen Peptides Manufacturing Market Snapshot
Chapter 4. Global Neoantigen Peptides Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter's Five Forces Analysis
4.6. Investment and Funding Analysis for Neoantigen Vaccine and Therapeutic Development
4.7. Clinical Trial/Pipeline Analysis for Neoantigen Cancer Vaccine
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Scale of Operations Estimates & Trend Analysis
5.1. By Scale of Operations & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Scale of Operations:
5.2.1. Research / Preclinical
5.2.2. Clinical
5.2.3. Commercial
Chapter 6. Market Segmentation 2: By End-Users Estimates & Trend Analysis
6.1. By End-Users & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-Users:
6.2.1. Pharmaceutical/Vaccine Developers Companies
6.2.2. Contract Research Organization (CRO)
6.2.3. Academic and Research Institutes
Chapter 7. Neoantigen Peptides Manufacturing Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts By Scale of Operations, 2021-2034
7.1.2. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts By Therapy, 2021-2034
7.1.3. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2021-2034
7.1.4. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2021-2034
7.2.2. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2021-2034
7.2.3. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2021-2034
7.2.4. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2021-2034
7.3.2. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2021-2034
7.3.3. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2021-2034
7.3.4. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2021-2034
7.4.2. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2021-2034
7.4.3. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2021-2034
7.4.4. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2021-2034
7.5.2. Middle East & Africa Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. CPC Scientific Inc
8.2.2. Polypeptide group
8.2.3. Genscript Biotech
8.2.4. Kaneka Eurogentec S.A.
8.2.5. Vivitide
8.2.6. Almac
8.2.7. BCN Peptides
8.2.8. Creative Peptides
8.2.9. Pepscan
8.2.10. Provepharm
8.2.11. Creosalus
8.2.12. Gyros Protein Technologies
8.2.13.AnaSpec
8.2.14. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們